No Data
Sanofi Opens New $600 Million Vaccines Facility in Singapore
Pharmaceutical giant Sanofi has invested nearly 0.6 billion dollars to build a factory in Singapore to produce vaccines.
French pharmaceutical giant Sanofi announced on Wednesday that it will build a new factory in Singapore to produce vaccines and other pharmaceuticals to enhance preparedness for emergencies, including potential pandemics. According to a statement, the factory named Modulus is being constructed with an investment of 0.8 billion Singapore dollars (almost 0.6 billion US dollars) in the Biopharmaceutical Park in Tuas, Singapore. It can simultaneously produce up to four types of vaccines or biopharmaceuticals and is expected to be fully operational by mid-2026, creating 200 technical jobs in Singapore. The company stated that Modulus can also be reconfigured within days to switch between technical platforms.
Sanofi (SNY.US)/Regeneron (REGN.US) Dupilumab Injection approved again for clinical treatment of pure moss disease in China
A new clinical trial implied consent has been granted for the duperimabd injection declared by Sanofi (SNY.US).
Bird Flu Found In Raw Milk Leads To Recall In California
NSC, Sanofi, and A*STAR Partner to Advance Acne Treatment Research
MNOV: Monetary Damages Due Following Sanofi/Novartis Patent Dispute Settlement...
No Data
No Data
